Product NDC: | 51079-204 |
Proprietary Name: | Abacavir Sulfate |
Non Proprietary Name: | abacavir sulfate |
Active Ingredient(s): | 300 mg/1 & nbsp; abacavir sulfate |
Administration Route(s): | ORAL |
Dosage Form(s): | TABLET, FILM COATED |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 51079-204 |
Labeler Name: | Mylan Institutional Inc. |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | ANDA091294 |
Marketing Category: | ANDA |
Start Marketing Date: | 20130218 |
Package NDC: | 51079-204-06 |
Package Description: | 50 BLISTER PACK in 1 BOX, UNIT-DOSE (51079-204-06) > 1 TABLET, FILM COATED in 1 BLISTER PACK (51079-204-01) |
NDC Code | 51079-204-06 |
Proprietary Name | Abacavir Sulfate |
Package Description | 50 BLISTER PACK in 1 BOX, UNIT-DOSE (51079-204-06) > 1 TABLET, FILM COATED in 1 BLISTER PACK (51079-204-01) |
Product NDC | 51079-204 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | abacavir sulfate |
Dosage Form Name | TABLET, FILM COATED |
Route Name | ORAL |
Start Marketing Date | 20130218 |
Marketing Category Name | ANDA |
Labeler Name | Mylan Institutional Inc. |
Substance Name | ABACAVIR SULFATE |
Strength Number | 300 |
Strength Unit | mg/1 |
Pharmaceutical Classes | Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] |